$1.410
-0.168 (-11.88%)Al cierre
Noticias de PDSB
Eventos de PDSB
Selling Stockholders Plan to Sell 16.5M Shares of Common Stock
This filing relates to the offer and sale from time to time by the selling stockholders of up to 16.5M shares of common stock. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.
PDS Biotechnology Borrow Rate Increases to 10.40%
Latest data shows the largest indicative borrow rate increases among liquid option names include: PDS Biotechnology Corp (PDSB) 10.40% +6.80, Defiance Daily Target 2X Long RKLB ETF (RKLX) 20.22% +3.70, NRG Energy (NRG) 3.68% +3.27, Ruger (RGR) 5.77% +1.24, ProShares Trust (SPCF) 36.46% +0.37, Arbutus Biopharma (ABUS) 1.21% +0.25, ISHARES ETHEREUM TRUST ETF (ETHA) 0.68% +0.22, Astex Pharmaceuticals Inc (ASTX) 6.60% +0.21, Rezolve AI Ltd (RZLV) 21.51% +0.21, and MercadoLibre (MELI) 0.55% +0.19.
Vail Resorts Borrow Rate Increases to 31.04%
Latest data shows the largest indicative borrow rate increases among liquid option names include: Vail Resorts (MTN) 31.04% +26.78, GraniteShares 2x Long IONQ Daily ETF (IONL) 17.47% +3.47, Ruger (RGR) 9.74% +1.81, SES AI Corp (SES) 51.31% +1.19, Communication Services Select Sector SPDR Fund (XLC) 1.63% +1.11, T-REX 2X LONG MSTR DAILY TARGET (MSTU) 17.45% +0.50, PDS Biotechnology Corp (PDSB) 3.43% +0.49, Aries I Acquisition Corp (RAM) 8.73% +0.28, Rackspace Technology (RXT) 2.06% +0.25, and Direxion Daily 20 plus Year Treasury Bear 3X Shares (TMV) 44.86% +0.24.
PDS Biotechnology Publishes Phase 2 Trial Results for PDS0101
PDS Biotechnology announced the publication of results from a Phase 2 trial evaluating PDS0101, its HPV16-targeted immunotherapy, in combination with pembrolizumab in the September 17, 2026, issue of JAMA Oncology, a peer reviewed journal of the American Medical Association. Key findings: 62.3% of the ICI-naive participants in the mITT cohort had low CPS of 1-19, and 37.7% had high CPS greater than or equal to 20. In the overall CPS greater than or equal to 1 population, the mOS was 39.3 months; Objective response rate for CPS greater than or equal to 1 was 36% of which 5/53 were complete responders by investigator review and 34% of which 6/53 were complete responders by central review: The published ORR for the overall population with CPS greater than or equal to 1 when treated with standard of care pembrolizumab is 19%; The treatment was well-tolerated with 13.8% Grade greater than or equal to3 treatment-related adverse events, 1 Grade 4 event one year after PDS0101 therapy, and no Grade 5 TRAEs; The published safety profile for the overall population with CPS greater than or equal to 1 when treated with standard of care pembrolizumab reports 17% Grade greater than or equal to 3 TRAEs
NantBio Adds CFO to Board of Directors
Effective as of the Initial Closing, Dr. Soon-Shiong and James Banaag, who currently serves the as chief financial officer of NantBio, Inc., will join the company's board of directors.
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.